Key points are not available for this paper at this time.
Combination therapy with TOF might have the potential to control refractory anti-MDA5 Ab+ DM-ILD.
Kurasawa et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: